ArticleTranslational cancer research2026
Efficacy and safety of National Centralized Drug Procurement-procured versus non-National Centralized Drug Procurement oxaliplatin in unresectable or metastatic pancreatic cancer: a retrospective cohort study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China's National Centralized Drug Procurement (NCDP) policy has substantially reduced the cost of essential medicines, yet concerns persist regarding the real-world therapeutic equivalence of NCDP-procured drugs compared to their non-NCDP counterparts. This study aimed to systematically evaluate, using real-world data, the comparative efficacy and safety of NCDP-procured versus non-NCDP oxaliplatin in patients with advanced pancreatic cancer. Methods: This single-center retrospective cohort study enrolled patients with unresectable or metastatic pancreatic cancer who received first-line mFOLFIRINOX between May 2022 and March 2025. Patients were stratified into NCDP and non-NCDP groups based on the procurement source of oxaliplatin. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Safety was assessed by the incidence of adverse drug reactions (ADRs). Results: Among 168 enrolled patients (NCDP, n=77; non-NCDP, n=91), no significant between-group differences were observed in ORR (9.1% Conclusions: NCDP-procured oxaliplatin demonstrated comparable efficacy to non-NCDP alternatives in advanced pancreatic cancer, with a more favorable safety profile for specific hepatic and hematologic toxicities. These real-world findings support the translation of the national procurement policy into clinical practice, offering significant cost savings without compromising patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.